Significance of Peripheral Blood Neutrophil to Lymphocyte Ratio in the Prognosis of Breast Cancer
Abstract: Objective: We performed this study of breast cancer patients to evaluate the prognostic value of the NLR. Methods: We retrospectively analyzed 263 cases of breast cancer patients treated in The First Hospital of Qinhuangdao after pathology diagnosis from January 2009 to January 2011. According to the ROC curve, while taking into account the sensitivity and specificity, we selected NLR = 2.08 as the cut-off value, and divided the patients into low NLR group (NLR < 2.08) and high NLR group (NLR > 2.08). Statistical analysis was performed with the statistical package for the social sciences (SPSS) software package version 19.0. We explore the relationship between NLR and clinical factors on prognosis by calculating 5-year survival rate. Results: 1) In term of age, history of cancer and menopausal status, there was no statistically significant difference. NLR difference between lower and upper groups has statistics significance (P < 0.05) on leukocyte counts before treatment. 2) In this study, 5-year survival rate of 263 cases of breast cancer was 80.23%. In NLR > 2.08 group, it was 65.00%; in NLR < 2.08 group, it was 89.57%. The difference was statistically significant (P < 0.01). 3) The high and low NLR groups have no statistics significance in Luminal B subtype and Her-2 subtype, while it has statistics significance (P < 0.05) in Luminal A subtype and triple-negative subtype. 4) NLR and molecular subtype were identified as independent prognostic factors for survival (P < 0.05). Conclusion: Prognosis in patients with NLR > 2.08 is worse than that in patients with NLR < 2.08. NLR, clinical stages and the molecular subtype are independent factors which influence the prognosis of breast cancer patients.
文章引用: 王真真 , 杨雁鸿 , 冯 博 , 冯 悦 , 李倩影 , 王小玉 (2016) 外周血中性粒细胞与淋巴细胞比值在乳腺癌各分子分型预后中的意义。 亚洲肿瘤科病例研究， 5， 14-25. doi: 10.12677/ACRPO.2016.51002
Jemal, A., Bray, F., Center, M.M., et al. (2011) Global Cancer Statistics. CA: A Cancer Journal for Clinicians, 61, 69- 90.
Schnitt, S.J. (2010) Classification and Prognosis of Invasive Breast Cancer: From Morphology to Molecular Taxonomy. Modern Pathology, 23, S60-S64.
Rakha, E.A. and Ellis, I.O. (2011) Modern Classification of Breast Cancer: Should We Stick with Morphology or Convert to Molecular Profile Characteristics. Advances in Anatomic Pathology, 18, 255-267.
Clark, E.J., Connor, S., Taylor, M.A., et al. (2007) Preoperative Lymphocyte Count as a Prognostic Factor in Resected Pancreatic Ductal Adenocarcinoma. HPB (Oxford), 9, 456-460.
Fridlender, Z.G., Sun, J., Kim, S., et al. (2009) Polarization of Tu-mor-Associated Neutrophil Phenotype by TGF-Beta: “N1” versus “N2” TAN. Cancer Cell, 16, 183-194.
 郭鹏, 叶颖江, 尹慕军, 等. 格拉斯哥预后评分可用作结肠癌预后的指标[J]. 中华普通外科杂志, 2011, 26(7): 557-561.
Sarraf, K.M., Belcher, E., Raevsky, E., et al. (2009) Neutrophil/Lymphocyte Ratio and Its Association with Survival after Complete Resection in Non-Small Cell Lung Cancer. The Journal of Thoracic and Cardiovascular Surgery, 137, 425-428.
Urrejola, G.I., Bambs, C.E., Espinoza, M.A., et al. (2013) An Elevated Neutrophil/Lymphocyte Ratio Is Associated with Poor Prognosis in Stage II Resected Colon Cancer. Revista Médica de Chile, 141, 602-608.
Lee, S., Oh, S.Y., Kim, S.H., et al. (2013) Prognostic Significance of Neutrophil Lymphocyte Ratio and Platelet Lymphocyte Ratio in Advanced Gastric Cancer Patients Treated with FOLFOX Chemotherapy. BMC Cancer, 13, 350.
Lai, Q., Castro Santa, E., Rico Juri, J.M., et al. (2014) Neutrophil and Platelet-to-Lymphocyte Ratio as New Predictors of Dropout and Recurrence after Liver Transplantation for Hepatocellular Cancer. Transplant International, 27, 32-41.
Stotz, M., Gerger, A., Eisner, F., et al. (2013) Increased Neutrophil-Lymphocyte Ratio Is A Poor Prognostic Factor in Patients with Primary Operable and Inoperable Pancreatic Cancer. British Journal of Cancer, 109, 416-421.
Feng, J.F., Huang, Y. and Chen, Q.X. (2014) Preoperative Platelet Lymphocyte Ratio (PLR) Is Superior to Neutrophil Lymphocyte Ratio (NLR) as a Predictive Factor in Patients with Esophageal Squamous Cell Carcinoma. World Journal of Surgical Oncology, 12, 58.
Noh, H., Eomm, M., Han, A., et al. (2013) Usefulness of Pretreatment Neutrophil to Lymphocyte Ratio in Predicting Disease-Specific Survival in Breast Cancer Patients. Journal of Breast Cancer, 16, 55-9.
Azab, B., Bhatt, V.R., Phookan, J., et al. (2012) Usefulness of the Neutro-phil-to-Lymphocyte Ratio in Predicting Short- and Long-Term Mortality in Breast Cancer Patients. Annals of Surgical Oncology, 19, 17-224.
 Forget, P., Bentin, C., Machiels, J.P., et al. (2014) Intraoperative Use of Ketorolac or Diclofenac Is Associated with Improved Disease-Free Survival and Overall Survival in Conservative Breast Cancer. Surgery, 113, 82-87.
王腾, 常树建, 沈娣, 等. 血常规参数对乳腺癌预后的判断价值[J]. 中华临床医师杂志(电子版), 2012, 6(17): 5100-5104.
 钱鹏, 恽华忠, 朱玲, 等. 炎性指标在乳腺癌术前诊断和预后评估中的价值[J]. 检验医学与临床, 2015, 12(24): 3765-3767.
 Nakano, K., Hosoda, M., Yamamoto, M. and Yamashita, H. (2014) Prognostic Significance of Pretreatment Neutrophil-Lymphocyte ratio in Japanese Patients with Breast Cancer. Anticancer Research, 34, 3819-3824.
Baeriswyl, V. and Christofori, G. (2009) The Angiogenic Switch in Carcinogenesis. Seminars in Cancer Biology, 19, 329-337.
Balkwill, F. and Mantovani, A. (2001) Inflammation and Cancer: Back to Virchow? Lancet, 357, 539-545.
 王宁舫, 洪群英. 肺癌转移的炎症微环境机制研究进展[J]. 国际呼吸杂志, 2014, 34(24): 1905-1908.
De Larco, J.E., Wuertz, B.R. and Furcht, L.T. (2004) The Potential Role of Neutrophils in Promoting the Metastatic Phenotype of Tumors Releasing Interleuking. Clinical Cancer Research, 10, 4895-4900.
Dumitru, C.A., Lang, S. and Brandau, S. (2013) Modulmion of Neutrophil Granulocytes in the Tumor Microenvironment, Mechanisms and Consequences for Tumor Progression. Seminars in Cancer Biology, 23, 141-148.
Tazzyman, S., Niaz, H. and Murdoch, C. (2013) Neutrophil-Mediated Tumour Angiogenesis, Subversion of Immune Responses to Promote Tumour Growth. Seminars in Cancer Biology, 23, 149-158.
Spicer, J.D., McDonald, B., Cools-Lartigue, J.J., et al. (2012) Neutrophils Promote Liver Metastasis via Mac-L-Med- iated Interactions with Circulating Tumor Cells. Cancer Research, 72, 3919-3927.
Queen, M.M. and Ryan, R.E. (2005) Breast Cancer Cells Stimulate Neutrophils to Produce Oncostatin M, Potential Implications for Tumor Progression. Cancer Research, 65, 8896-8904.
Dumitru, C.A., Moses, K., Trellakis, S. Lang, S. and Brandau, S. (2012) Neutrophils and Granulocytic Myeloid-Derived Suppressor Cells, Immtmophenotyping, Cell Biology and Clinical Relevance in Human Oncology. Cancer Immunology, Immunotherapy, 61, 1155-1167.
 Zhang, H.M., Zhang, B.N., Xuan, L.X. and Zhao, P. (2009) Clinical Characteristics and Survival in the Operable Breast Cancer Patients with Different Molecular Subtypes. Chinese Journal of Oncology, 31, 447-451.
Ihemelandu, C.U., Leffall Jr., L.D., Dewitty, R.L., et al. (2007) Molecular Breast Cancer Subtypes in Premenopausal and Postmenopausal African-American Women, Age-Specific Prevalence and Survival. Journal of Surgical Research, 143, 109-118.
Place, A.E., Jin Huh, S. and Polyak, K. (2011) The Microenvironment in Breast Cancer Progression: Biology and Implications for Treatment. Breast Cancer Research, 13, 227.
Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast Cancer and Hormone Replacement Therapy, Collaborative Reanalysis of Data from 51 Epidemiological Studies of 52,705 Women with Breast Cancer and 108,411 Women without Breast Cancer. Lancet, 350, 1047-1059.
Chlebowski, R.T., Anderson, G.L., Gass, M., et al. (2010) Estrogen plus Progestin and Breast Cancer Incidence and Mortality in Postmenopausal Women. JAMA, 304, 1684-1692.
Feigelson, H.S., Jonas, C.R., Teras, L.R., et al. (2004) Weight Gain, Body Mass Index, Hormone Replacement Therapy, and Postmenopausal Breast Cancer in a Large Prospective Study. Cancer Epidemiology, Biomarkers & Prevention, 13, 220-224.
Adams, S., Gray, R.J., Demaria, S., et al. (2014) Prognostic Value of Tumorinfiltrating Lymphocytes in Triple-Nega- tive Breast Cancers from Two Phase III Randomized Adjuvant Breast Cancer Trials, ECOG 2197 and ECOG 1199. Journal of Clinical Oncology, 32, 2959-2966.
Retsky, M., Rogers, R., Demicheli, R., et al. (2012) NSAID Analgesic Ketorolac Used Perioperatively May Suppress Early Breast Cancer Relapse: Particular Relevance to Triple Negative Subgroup. Breast Cancer Research and Treatment, 134, 881-888.
Loi, S., Sirtaine, N., Piette, F., et al. (2013) Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin with Doxorubicin-Based Chemotherapy: BIG 02-98. Journal of Clinical Oncology, 31, 860-867.
Denkert, C., Loibl, S., Noske, A., et al. (2010) Tumor-Associated Lymphocytes as an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer. Journal of Clinical Oncology, 28, 105-113.
Liu, S., Lachapelle, J., Lenung, S., Gao, D., Foulkes, W.D. and Nielsen, T.O. (2012) CD8+ Lymphocyte Infiltration Is an Independent Favorable Prognostic Indicator in Basal-Like Breast Cancer. Breast Cancer Research, 14, R48.
Engel, J.B., Honig, A., Kapp, M., et al. (2014) Mechanisms of Tumor Immune Escape in Triple-Negative Breast Cancers (TNBC) with and without Mutated BRCA 1. Archives of Gynecology and Obstetrics, 289, 141-147.
Buyukkaya, E., Karakas, M.F., Karakas, E., et al. (2014) Correlation of Neutrophil to Lymphocyte Ratio with the Presence and Severity of Metabolic Syndrome. Clinical and Applied Thrombosis/Hemostasis, 20, 159-163.